Prednisone is linked to mood swings in patients with IBD

  • Ou G & al.
  • J Can Assoc Gastroenterol
  • 1 Sep 2018

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The corticosteroid prednisone is linked to a high rate of mood changes in patients being treated for flare-ups of inflammatory bowel disease (IBD).

Why this matters

  • More research is needed to find ways to minimise these adverse events; in the meantime, healthcare providers should inform patients before starting corticosteroid therapy for IBD, and monitor them closely during treatment.

Study design

  • Researchers studied adult outpatients treated with prednisone for IBD flare-ups (N=53; mean age, 40±15 years; age range, 21-68 years; 49.1% women).
  • They assessed patient mood states with the Beck Depression Inventory II and the Activation subscale of Internal State Scale version 2, and monitored disease activity with the Harvey-Bradshaw Index and Simple Clinical Colitis Activity Index.
  • Funding: Procter & Gamble-Canadian Association of Gastroenterology Resident Research Award.

Key results

  • The rate of patient mood changes after a median of 15 (range, 7-32) days of treatment was 49.1%.
  • All but 1 of these patients had increases in manic symptoms that returned to pretreatment levels after treatment was complete; 4 had concomitant depression.

Limitations

  • The study was single-centre with a small sample and no control group.
  • Researchers did not monitor patient adherence to corticosteroid therapy.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit